An αIL-4 mAb (Pascolizumab®) has been tested for allergies and pulmonary tuberculosis (NCT01638520), and other therapeutics targeting IL-4 (e.g., Altrakincept®), IL-4Rα (e.g., Dupilumab®, AMG-317, and Pitrakinra®) are under development for treatment of atopic dermatitis, allergies, autoimmune disorders, or other indications32. The gene discussed is IL4R; the disease is allergic disease.